Dysregulation of RTK-RAS signaling is a key driver of tumorigenesis. Overexpression or mutation of RTKs can lead to aberrant activation of RAS, contributing to cancer development.
Due to their central role in cancer, both RTKs and RAS proteins are important targets for cancer therapies. Inhibitors targeting RTKs (e.g., EGFR inhibitors) and RAS (e.g., direct RAS inhibitors) are being developed and tested in clinical settings.
(Will delete Record if Target field = "Delete") Home